Examining the immune environment and gene expression in mesothelioma
From Immune Microenvironment Characterization and Gene Expression Profiling to New Drugs Testing in Pleural and Peritoneal Mesothelioma: Imaging-Meso Study
This study is trying to learn more about the immune system and genes in patients with rare mesothelioma cancers to find better, personalized treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 220 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istituto Oncologico Veneto IRCCS Academic / other |
| Drugs / interventions | ipilimumab, nivolumab |
| Locations | 10 sites (Rozzano, Milano and 9 other locations) |
| Trial ID | NCT06581549 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on pleural and peritoneal mesotheliomas, rare cancers primarily linked to asbestos exposure. It aims to enhance the understanding of the immune microenvironment and gene expression profiles in these tumors, which are characterized by significant genomic heterogeneity and poor prognosis. By analyzing tumor samples from patients undergoing surgery, the study seeks to identify molecular subgroups that could lead to personalized treatment strategies. The findings may help address the current lack of effective treatment sequences for patients with this condition.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with confirmed pleural or peritoneal mesothelioma who have undergone surgery and are in follow-up after active cancer treatment.
Not a fit: Patients who are not amenable to active oncologic treatment or those with inadequate biological material for analysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved personalized treatment options for patients with mesothelioma.
How similar studies have performed: While the approach of analyzing the immune microenvironment in mesothelioma is gaining traction, this specific study's focus on gene expression profiling in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Mesothelioma of the Pleura and Peritoneum * Age greater than 18 years of age * Patients undergoing surgery will require both biopsy and surgical sampling material * Pathologist's confirmation of the presence of tumor sections in the excised specimens * Patients in follow-up from active cancer treatment for at least 6 months Exclusion Criteria: * Inadequacy of biological material for analysis under study * Patients not amenable to active oncologic treatment * Patients lost to follow-up before 6 months after the end of active oncologic treatment
Where this trial is running
Rozzano, Milano and 9 other locations
- Istituto Clinico Humanitas — Rozzano, Milano, Italy (Recruiting)
- Centro di Riferimento Oncologico (CRO) IRCCS — Aviano, Pordenone, Italy (Recruiting)
- Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo — Alessandria, Italy (Recruiting)
- Asst Papa Giovanni Xxiii Bergamo — Bergamo, Italy (Recruiting)
- Ircss Ospedale Policlinico San Martino — Genova, Italy (Recruiting)
- Asst Grande Ospedale Metropolitano Niguarda-Milano — Milan, Italy (Recruiting)
- Fondazione Ircss Istituto Nazionale Dei Tumori Di Milano — Milan, Italy (Recruiting)
- Istituto Oncologico Veneto — Padova, Italy (Recruiting)
- Azienda Ospedaliera-Universitaria di Parma — Parma, Italy (Recruiting)
- Azienda Ospedaliera Universitaria Integrata Verona — Verona, Italy (Recruiting)
Study contacts
- Principal investigator: Giulia Pasello, MD — Istituto Oncologico Veneto IOV IRCCS
- Study coordinator: Giulia Pasello, MD
- Email: giulia.pasello@iov.veneto.it
- Phone: 0498215608
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.